HTBT is a high-tech bio-pharmaceutical enterprise that specializes in the R&D and production of the second- and third-generation recombinant human insulin APIs and preparations. The company produced the first batch of high-purity insulin crystals in November 2013 and its insulin preparations are soon to enter the clinical trial phase. In addition, HTBT has introduced Liu Changxiao's academician team to set up an academician workstation, which will accelerate HTBT's R&D of new drugs by taking the academic and technological advantages of China's only national key laboratory of pharmacokinetics, and will get authoritative guidance in the introduction of new drugs. The two parties will also cooperate on talent development to enrich HTBT's talent pool as well as provide a good experimental base for talent development of research institutes.
Academician Liu Changxiao has been engaged in pharmacokinetics research for 40 years, and is one of the pioneers and leaders of China's pharmacokinetics discipline. From 1968, Liu initiated the establishment of the first domestic laboratory of pharmacokinetics, applied pharmacokinetics research to the evaluation and identification of new drugs for the first time in China, punished the first domestic monograph on pharmacokinetics, and created a number of key laboratories of pharmacokinetics. In 1992, Liu received the government subsidy of the State Council. Liu was awarded as Advanced Worker, Labor Model and National Labor Model.
Up to now, our area has three academician workstations, which will provide strong support for local economic development and transformation. (Second Investment Promotion Bureau)motion Bureau)